Axsome Therapeutics (AXSM) saw its stock rise by 5.41% as it reached a 5-day high amid positive revenue projections.
The company anticipates approximately $196 million in product revenue for Q4 2025, reflecting a robust 65% year-over-year growth compared to Q4 2024. Additionally, Axsome projects total product revenue of about $638.5 million for the full year 2025, representing a 66% annual growth. This growth is driven by strong sales of AUVELITY, which is expected to reach approximately $155.1 million in Q4 2025, showcasing strong market acceptance and sales potential for this product.
These projections indicate Axsome's continued expansion in market share and profitability, likely attracting increased investor interest as the company solidifies its position in the biopharmaceutical sector.
Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 175.25 USD with a low forecast of 148.00 USD and a high forecast of 202.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 175.25 USD with a low forecast of 148.00 USD and a high forecast of 202.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 174.140
Low
148.00
Averages
175.25
High
202.00
Current: 174.140
Low
148.00
Averages
175.25
High
202.00
Morgan Stanley
Overweight -> Equal Weight
downgrade
$196 -> $204
Al Analysis
2026-01-08
Reason
Morgan Stanley
Price Target
$196 -> $204
Al Analysis
2026-01-08
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Axsome Therapeutics to Equal Weight from Overweight with a price target of $204, up from $196. Axsome announced on December 31 that the FDA accepted the AXS-05 sNDA for Alzheimer's Disease Agitation with Priority Review, immediately driving a sharp stock reaction, notes the analyst, who increased the firm's view of the probability of success for AXS05 in ADA to 85% from 75%. However, the post-event run-up has meaningfully reduced near-term upside from current levels, says the analyst, who views 2026 as "relatively catalyst-light" outside of the April-end PDUFA date for AXS-05 in ADA.
UBS
NULL -> Buy
upgrade
$163 -> $248
2026-01-06
Reason
UBS
Price Target
$163 -> $248
2026-01-06
upgrade
NULL -> Buy
Reason
UBS raised the firm's price target on Axsome Therapeutics to $248 from $163 and keeps a Buy rating on the shares. The Biotech sector enters 2026 on a cautiously optimistic note, the analyst tells investors in a research note. While capital absorption from secondary offerings is a concern, over $47B of pending capital from potential M&A could offset this, though sustained outperformance will likely require M&A activity to continue outpacing secondaries and IPOs, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AXSM
Unlock Now
Needham
Ami Fadia
Buy
maintain
$169 -> $225
2026-01-05
Reason
Needham
Ami Fadia
Price Target
$169 -> $225
2026-01-05
maintain
Buy
Reason
Needham analyst Ami Fadia raised the firm's price target on Axsome Therapeutics to $225 from $169 and keeps a Buy rating on the shares. The firm sees traction in 2026 for the company, based on potential approval and launch of Auvelity in Alzheimer's disease agitation and pipeline development. Needham also expects continued strong performance of Auvelity in major depressive disorder.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$185 -> $200
2026-01-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$185 -> $200
2026-01-05
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Axsome Therapeutics to $200 from $185 and keeps a Buy rating on the shares after the AXS-05 regulatory application was accepted with priority review. The firm increased its market penetration assumptions for AXS-05 given the potential for regulatory approval and market entry during the first half of 2026.
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
